CARMA family: an overview {#s1}
=========================

Caspase recruitment domain (CARD)-containing membrane-associated guanylate kinase (MAGUK) proteins constitute a family of three scaffold proteins, highly conserved in their amino acidic sequence, named CARD11/CARMA1 (CARMA1), CARD14/CARMA2 (CARMA2), and CARD10/CARMA3 (CARMA3) ([@B1], [@B2]). CARMA proteins were identified in 2001, while screening sequence databases and two-hybrid libraries for novel CARD-containing proteins, and were shown to be able to interact with the CARD domain of B-Cell Leukemia 10 (BCL10) ([@B3]--[@B6]). The human CARMA proteins are encoded by three conserved genes, respectively located on chromosomes 7, 17, and 22. Structurally, CARMA proteins are characterized by a typical modular organization, with the CARD domain at the N-terminus, followed by a Coiled-Coil region and a C-terminal MAGUK domain, consisting of PDZ, SH3, and GUK modules (Figure [1A](#F1){ref-type="fig"}). Despite the high degree of structural similarity, the expression pattern of each CARMA protein is restricted to distinct tissues, where they are involved in cell-specific signaling pathways that control activation of NF-κB, a pleiotropic transcription factor that controls transcription of, among others, immunomodulatory and inflammatory genes and genes that generally promote cell proliferation and survival ([@B7]). Indeed, CARMA1 is mainly expressed in lymphoid cells and hematopoietic tissues, where it mediates NF-κB induction following antigen receptor engagement. Notably, CARMA1 deficient-mice show a severe defect in lymphocyte proliferation following T- and B-cell receptor stimulation, with impaired production and release of cytokines ([@B8]--[@B10]), due to defective NF-κB activation. Consistently with evidences from animal models, whereas loss-of-function mutations in human *CARMA1* gene cause severe forms of immunodeficiencies ([@B11]--[@B13]), gain-of-function mutations have been frequently described in patients affected by diverse lymphoid malignancies, such as T-cell lymphomas, gastric B-cell lymphomas, some non-Hodgkin\'s lymphomas and others ([@B14]).

![Schematic representation of domain organization of **(A)** CARD11/CARMA1 (UniProt Entry: [UniProt](Q9BXL7)) and CARD10/CARMA3 (UniProt Entry: [Q9BWT7](Q9BWT7)) proteins, **(B)** CARD14/CARMA2 isoforms (UniProt Entry: [Q9BXL6](Q9BXL6)) **(C)** BCL10 (UniProt Entry: [O95999](O95999)) and MALT1 proteins (UniProt Entry: [Q9UDY8](Q9UDY8)). Aminoacid numbering and domains are referred to human proteins. CARD, CAspase-Recruitment Domain; PDZ, post-synaptic density protein (PSD95), Drosophila disc large tumor suppressor (Dlg1), and Zonula occludens-1 protein (Zo-1) domain; GuK, guanylate kinase-like; DEATH, death domain; SH3, Src homology 3; Ig-LIKE, immunoglobulin-like domain; COILED COIL, coiled coil region; CASPASE-LIKE, Cysteine-ASpartic ProteASEs-like domain.](fimmu-09-02167-g0001){#F1}

Conversely, CARMA2 and CARMA3 are both expressed in non-lymphoid tissues, but in a non-overlapping manner. In fact, CARMA2 protein is preferentially expressed in epithelial cells of the skin and in mucosae, while CARMA3 has a broader non-hematopoietic expression pattern ([@B2]). In these districts, CARMA3 regulates NF-κB activation following stimulation of G-protein coupled receptors (GPCRs) with several ligands, such as angiotensin II, endothelin I, and lyso-phosphatidic acid ([@B15], [@B16]). In addition, CARMA3 has also been shown to be involved in NF-κB activation downstream of the epithelial growth factor receptor ([@B17]). Not surprisingly, CARMA3 over-expression has been shown to be implicated in the onset and progression of different cancers by several studies ([@B18], [@B19]).

Compared to CARMA1 and CARMA3, CARMA2 is less characterized. Only recent studies have shed light on the crucial role this scaffold protein plays in the human skin, where it regulates tissue homeostasis.

CARMA2: cloning, splice variants, expression {#s2}
============================================

CARMA2 was originally identified as a placenta-specific cytoplasmic 1,004 amino acids protein containing a CARD module and a MAGUK domain, and capable to activate the NF-κB-controlled expression of a luciferase reporter gene when transfected in cultured cell lines ([@B3]). Subsequent works have demonstrated that *CARMA2* mRNA undergoes alternate splicing processes ([@B20]) and that the deriving protein isoforms show a wider distribution profile, being expressed also in epidermal keratinocytes, dermal endothelial cells, mucosae and different cell lines ([@B20], [@B21]). In particular, three transcript variants of human *CARMA2* gene have been identified, named CARMA2*fl* (*full length*; 1,004 amino acids), the longest polypeptide containing all the typical CARMA domains and modules; CARMA2*sh* (*short*; 740 amino acids), the prominent isoform expressed in the human skin, lacking the SH3 and GuK modules and containing the CARD, coiled coil and PDZ domains; and CARMA2*cl* (*cardless*; 434 amino acids), containing only a portion of the coiled coil domain, the linker region and a shorter PDZ module (Figure [1B](#F1){ref-type="fig"}). Due to the absence of a complete MAGUK domain, CARMA2*cl* and CARMA2*sh* variants may not be exclusively associated to the cell membrane, but rather distributed in the cytosol where they possibly transduce intracellular signals ([@B20]).

As assessed by NF-κB-luciferase reporter assays, while CARMA2*fl* and especially CARMA2*sh* are strong inducers of NF-κB, CARMA2*cl* is unable to promote activity of this transcription factor ([@B20]), confirming the CARD region as an essential domain for NF-κB signaling regulated by CARD-containing proteins. Indeed, similarly to CARMA1 and CARMA3, CARMA2*fl*, and CARMA2*sh*, but not CARMA2*cl*, interact with BCL10 via an homotypic CARD-CARD association and, together with the paracaspase Mucosa Associated lymphoid tissue Lymphoma Translocation protein 1 (MALT1), are able to form a CARMA-BCL10-MALT1 (CBM) complex (Figure [1C](#F1){ref-type="fig"}). Assembly of the CBM complex is crucial for the recruitment of downstream signaling components that lead to NF-κB activation ([@B20], [@B22], [@B23]). Differently from the longest CARMA2 isoforms, CARMA2*cl* has a very limited expression profile in non-epidermal tissue, and in transfection experiments it may function as a natural dominant-negative regulator of CARMA2*sh* signaling in the skin (Scudiero and Vito, unpublished results). Overall, the identification of alternative transcripts for *CARMA2* is intriguing for several reasons: first, their expression pattern is not totally overlapping, suggesting that they could play diverse functions in different cell types; second, even within the same cell type, *CARMA2* transcript variants could regulate different stimuli, starting both from the cell membrane and intracellular organules, or regulate signals from the same stimulus at several levels.

CARMA2 in keratinocytes and skin disorders {#s3}
==========================================

Psoriasis is an inflammatory disorder of the human skin, characterized by well-demarcated oval-shaped erythematous plaques on the skin due to abnormal keratinization and proliferation of superficial keratinocytes, and persistence of nucleated cells in the corneus layer ([@B24]). The onset of psoriasis depends on both genetic and environmental factors and is characterized by the disruption of the epithelial barrier function and tissue homeostasis due to stressing or traumatic events within the epidermis, and a dysregulated immune response. Epidemiologic studies based on data collected on psoriatic patients from 20 different countries show that psoriasis is a complex genetic-based immune-mediated disease with a prevalence ranging from 0 to 1.37% in children and from 0.51 to 11.43% in adults, with at least 100 million individuals affected worldwide ([@B25]). Indeed, in the human genome multiple susceptibility loci, collectively called *PSORS*s, have been associated to the familial transmission of the psoriatic tract, with the identification of about 40 genes involved in antigen presentation, interleukin and cytokine signaling, antiviral response, NF-κB signaling and, more generally, in the adaptive and innate immunity ([@B24]). Nevertheless, although a genetic base underlies psoriasis and psoriasis-related diseases, \<20% of disease variance is explained by mutations in the aforementioned genes, suggesting the existence of additional mechanisms which could trigger these skin inflammatory pathologies ([@B26]).

In 2012, Jordan et al. established that *PSORS2* was due to gain-of-function mutations in the *CARD14* gene, as assessed by exome capture and next generation sequencing over genomic DNA from both familial and sporadic cases of psoriasis and psoriatic arthritis ([@B27], [@B28]). Most of the psoriasis-linked mutations harbored in CARMA2*sh* produced an enhanced activity of NF-κB transcription factor in luciferase assays, with a consequent up-regulation of NF-κB-induced inflammatory transcripts in keratinocytes, such as CXCL8, CCL20, IL8, and IL6, confirming the crucial role played by this transcription factor in epithelial homeostasis ([@B27], [@B28]). In addition to genetic psoriasis, mutations in *CARMA2* were also found in familial cases of pityriasis rubra pilaris, a papulosquamous disorder phenotypically related to psoriasis ([@B29]).

Subsequently, plenty of sequence variations and mutations in the *CARD14* gene have been mapped and associated to psoriasis, pityriasis and other skin disorders phenotipically related to them. Table [1](#T1){ref-type="table"} reports all known CARMA2*sh* variants associated to skin inflammatory illnesses that have been identified so far, updating a list already provided by Van Nuffel et al. ([@B50]). Figure [2](#F2){ref-type="fig"} show that base mutations preferentially involve codons in exon 4, resulting in amino acidic substitutions within the CARD and Coiled-Coil domains.

###### 

List of CARMA2 variants associated to psoriasis or psoriasiform inflammatory diesases.

  **Mutation**       **Disease**                                                                    **References**
  ------------------ ------------------------------------------------------------------------------ ----------------------------------
  R38C               Psoriasis vulgaris                                                             ([@B27])
  R62Q               Psoriasis vulgaris                                                             ([@B27], [@B30])
  R69W               Psoriasis vulgaris                                                             ([@B30])
  G117S              Psoriasis vulgaris; Pityriasis rubra pilaris                                   ([@B27], [@B28], [@B30]--[@B33])
  c.349 + 5G \> A    Psoriasis vulgaris                                                             ([@B27], [@B28])
  c.349 + 5G \> C    Psoriasis; Pityriasis rubra pilaris                                            ([@B34])
  c.349 + 1G \> A    Pityriasis rubra pilaris; Generalized pustular psoriasis                       ([@B29], [@B35])
  M119R              Pityriasis rubra pilaris                                                       ([@B36])
  M119T              Psoriasis; Pityriasis rubra pilaris                                            ([@B34])
  M119V              Generalized pustular psoriasis                                                 ([@B37])
  L124P              Pityriasis rubra pilaris                                                       ([@B38])
  C127S              Pityriasis rubra pilaris                                                       ([@B33])
  Q136L              Pityriasis rubra pilaris                                                       ([@B33])
  E138A              Generalized pustular psoriasis                                                 ([@B27], [@B28])
  E138K              Pityriasis rubra pilaris                                                       ([@B39], [@B40])
  E138del            Pityriasis rubra pilaris                                                       ([@B29])
  E142K              Psoriasis vulgaris                                                             ([@B27], [@B28])
  E142G              Psoriasis vulgaris                                                             ([@B27], [@B28])
  L150R              Psoriasis vulgaris                                                             ([@B27], [@B30])
  R151W              Psoriasis vulgaris                                                             ([@B30])
  R151Q              Psoriasis vulgaris                                                             ([@B30])
  L156P              Pityriasis rubra pilaris                                                       ([@B29])
  Q157P              Psoriasis; Pityriasis rubra pilaris                                            ([@B34])
  R166H              Generalized pustular psoriasis                                                 ([@B37])
  H171N              Psoriasis vulgaris                                                             ([@B27])
  D176H              Psoriasis vulgaris; Generalized pustular psoriasis; Pityriasis rubra pilaris   ([@B27], [@B41]--[@B45])
  R179H              Psoriasis vulgaris; Pityriasis rubra pilaris                                   ([@B27], [@B43])
  V191L              Psoriasis vulgaris                                                             ([@B27])
  E197K              Psoriasis vulgaris; Pityriasis rubra pilaris; Psoriatic arthritis              ([@B30], [@B43])
  S200N              Psoriasis vulgaris; Generalized pustular psoriasis; Pityriasis rubra pilaris   ([@B27], [@B30], [@B31], [@B43])
  L209P              Psoriasis vulgaris                                                             ([@B30])
  A216T              Psoriasis vulgaris                                                             ([@B30], [@B37], [@B44])
  D285G              Psoriasis vulgaris                                                             ([@B27])
  M338V              Psoriasis vulgaris                                                             ([@B30])
  T420A              Psoriasis vulgaris                                                             ([@B30])
  R430W              Acute generalized exanthematous pustulosis                                     ([@B46])
  c.1356 + 5G \> A   Psoriasis vulgaris                                                             ([@B30])
  T591M              Psoriasis vulgaris                                                             ([@B37])
  I593N              Psoriasis vulgaris                                                             ([@B27])
  S602L              Psoriasis vulgaris; Generalized pustular psoriasis; Pityriasis rubra pilaris   ([@B30])
  R682W              Psoriasis vulgaris; Generalized pustular psoriasis                             ([@B27], [@B37])
  G714S              Psoriasis vulgaris                                                             ([@B27])
  R820W              Psoriasis vulgaris; Psoriatic arthritis                                        ([@B27], [@B47]--[@B49])
  D973E              Psoriasis vulgaris                                                             ([@B27])

![CARD14/CARMA2 variants associated to skin inflammatory diseases (see also Table [1](#T1){ref-type="table"}). Arrows indicate mutated base positions within CARD14/CARMA2 exons and corresponding aminoacid substitution identified in psoriasiform patients. In red, missense mutations having a reported positive effect on NF-κB activation.](fimmu-09-02167-g0002){#F2}

Although many of the *CARMA2* mutations found in a variety of inflammatory disorders of the human skin point to an aberrant activation of NF-κB, it is worth noting that some patients carry mutations in CARMA2*sh* (such as Arg38Cys; Arg69Trp; Arg151Trp; His171Asn; Ser200Asn; Ala216Thr; Thr420Ala) that, at least in luciferase-based *in vitro* assays, do not determine a remarkably stronger activation of NF-κB ([@B28], [@B30], [@B50]), suggesting that CARMA2*sh* could participate to additional intracellular mechanisms regulating skin homeostasis. In fact, other studies have demonstrated that several CARMA2*sh* variant, including Arg820Trp, could significatively affect the response to anti-TNFα treatment in psoriasis patients, with interesting implications for optimal therapy settings ([@B51], [@B52]).

CARMA2 signaling {#s4}
================

Given its involvement in the pathogenesis of psoriasis, many efforts have focused on the understanding of the molecular mechanisms through which CARMA2*sh* regulates signaling cascades in human keratinocytes (Figure [3](#F3){ref-type="fig"}). Experimental data indicate that CARMA2*sh* signaling requires assembly of a molecular complex that, in addition to CARMA2*sh*, also includes the adapter protein BCL10 and the protease MALT1, as demonstrated by experiments conducted using short interfering RNAs, genome editing methods and chemical inhibitors ([@B20], [@B22], [@B53]). Most of the details that control assembly of the CBM complex and its activation derive from data obtained with CARMA1 in lymphocytes. In un-stimulated cells, CARMA1 is held in check by the inhibitory linker region, located between the coiled-coil domain and the PDZ domain. Following cell stimulation, such auto-inhibition is removed through PKCs-mediated phosphorylation of serine residues in the linker region, thereby facilitating BCL10 and MALT1 binding to the CARMA1 ([@B54], [@B55]). The assembly of the CBM complex eventually results in the recruitment of the IKK complex and the consequent NF-κB activation ([@B23]). The similarity of the mechanisms of activation of the different CARMA proteins is also suggested by the fact that ectopic expression of the deubiquitinase A20 inhibits activation of NF-κB mediated by each of the CARMA proteins ([@B20], [@B22], [@B56]). Consistently with the model that considers assembly of the CBM complex as a crucial point for activation of the NF-κB pathway, two highly penetrant psoriasis-linked CARMA2*sh* point mutations, Gly117Ser, and Glu138Ala, abrogate CARMA2 auto-inhibition and stimulate MALT1 protease activity, causing constitutive activation of the CBM complex and aberrant NF-κB-dependent induction of downstream inflammatory genes ([@B22], [@B53]). Interestingly, MALT1 deficiency or chemical inhibition of its catalytic activity can block hyperactivation of the inflammatory signaling program (including the induction of TNFα, IL17C, CXCL8, and HBD2 genes), triggered by pathogenic psoriasis-related CARMA2*sh* mutants or by cell stimulation with the fungal cell wall component zymosan or with *Staphilococcus aureus*, pointing to MALT1 as a potential target for therapeutic treatment of skin disorders caused by aberrant CARMA2*sh* signaling ([@B22], [@B50], [@B53], [@B57]). In addition to the component of the CBM complex, the NF-κB-inducing activity of CARMA2*sh* also requires the adapter molecule TRAF2 ([@B20]), although this evidence comes from experiments carried out in non-keratinocytic cell lines. In these cells, CARMA2*sh* expression protects cells from apoptosis induced by different stimuli, including ER stress ([@B20]).

![Schematic overview of intracellular pathways involving CARD14/CARMA2 variants in keratinocytes. In the skin, CARMA2-mediated signals are prompted by intracellular organelles, such as endoplasmic reticulum, and by surface receptors, such as Toll-Like Receptors (TLRs) and IL17-Receptor (IL17R) in response to Pathogen Associated Membrane Patterns (PAMPs) and IL17, respectively. While CARMA2cl would act as a natural negative regulator, CARMA2sh and CARMA2fl variants interact with BCL10 and MALT1, thereby forming CBM complex. In turn, CBM triggers a canonical NEMO-dependent NF-κB-activation pathway, mediated by the IκB Kinase complex (IKK complex), which leads to expression of target genes in the nucleus, such as keratins, antimicrobial compounds and inflammatory mediators. Negative and positive regulators of CARMA2sh identified so far are also reported in the figure.](fimmu-09-02167-g0003){#F3}

The psoriasis-associated CARMA2*sh* mutants Glu138Ala and Glu142Gly also escape the negative regulation exerted by two novel CARMA2*sh* interactors identified by two-hybrid screening in yeast, namely the serine/threonine kinase Unc-51 Like Autophagy Activating Kinase 2 (ULK2) and the E3 ubiquitin ligase Ring Finger protein 7 (RNF7) ([@B57]--[@B59]). Both ULK2 and RNF7 are indeed able to repress CARMA2*sh*-induced NF-κB activation, although through different mechanisms. In particular, ULK2 phosphorylates CARMA2*sh* and promotes lysosomal degradation of BCL10, whereas RNF7 alters the ubiquitination state of MALT1 and NEMO ([@B58], [@B59]). Intriguingly, a protein similar to RNF7, named RNF181, has been identified as an interactor of CARMA1 and functions as an E3 ubiquitin ligase to inhibit antigen receptor signaling to NF-κB downstream of CARMA1 ([@B60]). Conversely, the ability of CARMA2*sh* to activate NF-κB is positively regulated by the DEP domain-containing protein DEPDC7, which may be required to specifically convey on the CBM complex signals coming from activated G protein-coupled receptors ([@B61]).

Recent evidence indicates that CARMA2*sh* and MALT1 play a role in the signal transduction pathway that connects pathogen-associated molecular patterns recognition to NF-κB activation ([@B57], [@B58]). Microorganisms, such as bacterial and fungi cells display in fact pathogen-associated molecular patterns (PAMPs), which are molecules associated with groups of pathogens, and activate NF-κB upon agonistic binding to Pattern Recognition Receptors, including members of the Toll-like receptors (TLR) family expressed on human keratinocytes. Indeed, depletion of each of the components of the CBM complex significantly impairs expression of NF-κB target genes in human epithelia keratinocytes exposed to heat-killed *Escherichia coli, Sthaphylococcus aureus* or *Candida valida* ([@B58]). Altogether, these findings strengthen the existence of a causal link between microbial infections and the onset of psoriasis and encourage more efforts in further clarifying how exposure to PAMPs could determine disruption of skin homeostasis, inflammation and hyperproliferation in susceptible keratinocytes.

Animal models {#s5}
=============

Many interesting information can be inferred from the very recent generation of murine strains genetically modified in the *CARMA2* locus. Tanaka and colleagues generated CARMA2-deficient mice, which appear viable and healthy at birth and after, with normal epidermal and dermal tissue architecture ([@B62]). Interestingly, CARMA2^−/−^ mice are resistant to psoriasis provoked by intraperitoneal injection of recombinant IL-23 or treatment with imiquimod (IMQ) cream, an agonist of TLR7/TLR9. From these data, the authors suggest that CARMA2 is relevant for IL-23 receptor signaling in a population of IL-17- and IL-22-producing γδ T cells ([@B62]). The data, however, does not exclude the possibility that CARMA2 also controls the signaling cascade strarting from TLR7/TLR9.

In another study carried out by Mellet et al. ([@B63]), the psoriasic phenotype spontaneously develops in C57BL/6J mice harboring a CARMA2 mutation consisting in the deletion of a key glutamic acid residue at position 138 (CARMA2Δ138). Interestingly, while mice homozygous for E138 deletion show developmental abnormalities and die perinatally, heterozygous animals are viable, and a single copy of the gain-of-function mutation is sufficient to trigger psoriatic pathogenesis *in vivo*. Indeed, *CARD14*^Δ*E*138/+^ mice display all clinical and immunological features of chronic plaque-type psoriatic disease, with diffuse skin lesions characterized by epidermis thickening, persistence of hyperproliferating nucleated keratinocytes and immune cell infiltration in upper epidermal layers. In addition, affected skin from *CARD14*^Δ*E*138/+^ mice shows a transcriptome profile resembling the typical gene expression signature observed in human psoriatic plaques, including upregulation of hyperproliferative keratins, cytokines, chemokines and antimicrobial peptide-encoding genes. Consistently with previous findings, the pathologic skin phenotype displayed by this murine model is driven by the activation of IL23/IL17 axis, that promotes Th17 cell polarization via IL23, as confirmed by the fact that neutralization of IL23p19 with an antagonist antibody ameliorates disease symptoms, by reducing skin lesions and expression of inflammatory and anti-microbial genes ([@B63]). Similarly, the *CARD14*^*E*138*A*/+^ and *CARD14*^Δ*Q*136/+^ murine strains generated by Wang et al. also spontaneously develop psoriasis-like skin inflammation, which resulted from enhanced activation of the IL23/IL17 cytokine axis ([@B64]). Interestingly, these authors also show that CARMA2 associates with the ACT1-TRAF6 signaling complex, thereby mediating IL-17-induced NF-κB and MAPK signaling pathway activation, eventually responsible for expression of pro-inflammatory molecules.

Conclusions {#s6}
===========

After establishing that *PSORS2* is due to NF-κB-activating mutations in *CARMA2*, current scientific advances are shedding some light on the molecular mechanisms that link these mutations to the development of human inflammatory skin diseases. Indeed, although for a long time CARMA2 was the most unknown of CARMA proteins, its clear involvement in the incipit and progression of inflammatory human skin disorders has acted as a strong propeller to clarify the biological and molecular processes in which this protein is involved. In many ways, CARMA2 acts just like the similar CARMA1 and CARMA3 proteins, with the CBM complex representing the molecular motor driving the signals transmission. However, some aspects of the signal tranduction pathways controlled by CARMA2 remain elusive. For example, it is not yet clear exactly what types of stimuli are channeled through CARMA2 to trigger NF-κB activation. Data generated in cell lines implicate CARMA2 in the signal transduction pathways starting from intracellular organelles, such as the endoplasmic reticulum, and from TLR receptors. In these contexts, CARMA2 activity seems to be controlled by TRAFs proteins and by molecules involved in autophagic processes, such as ULK2. Furthermore, ubiquitination mechanisms in which RNF and DEPDC7 proteins are involved seem to play a role in the capacity of CARMA2 to regulate the activity of NF-κB transcription factor.

The recent generation of murine strains harboring genetic modifications in the *CARMA2* locus is undoubtedly another important tool that will offer great opportunities to study in a complex biological system the role CARMA2 plays in the physiology and pathology of keratinocytes. Psoriasis is a typically human disease, and probably the lack of animal models that spontaneously develop the same disease has certainly represented a limit to our knowledge of this disease. Taking into account the obvious differences existing between human skin and murine skin, the fact that *CARMA2*-modified mouse strains develop inflammatory disorders with features largely overlapping to human psoriasis represents a real breaktrough. The phenotypic analyzes conducted on these mice indicate that the main alteration resides in the signal transduction along the IL23/IL17 cytokine axis, that would be ultimately responsible for the development of the psoriatic phenotype.

The coming years will undoubtedly be decisive in placing all the knowledge we have acquired so far on CARMA2 in a clearer and more coherent picture.
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